

---

## BONESUPPORT Q3 - Surprising on US sales and EBIT

Redeye increases its fair value range following a closer look at the report. We were positively surprised by higher US CERAMENT G sales (ahead of any meaningful trauma indication contribution) and higher EBIT than we estimated. We make minor changes to our estimates on all time horizons and lower our WACC following a review of BONESUPPORT's qualities.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[BONESUPPORT Q3 - Surprising on US sales and EBIT](#)